33.96
-1.3866(-3.92%)
Currency In USD
| Previous Close | 35.35 |
| Open | 34.6 |
| Day High | 35.14 |
| Day Low | 33.88 |
| 52-Week High | 43.73 |
| 52-Week Low | 3.72 |
| Volume | 569,736 |
| Average Volume | 3.31M |
| Market Cap | 4.84B |
| PE | -16.57 |
| EPS | -2.05 |
| Moving Average 50 Days | 33.92 |
| Moving Average 200 Days | 15.69 |
| Change | -1.39 |
If you invested $1000 in Cogent Biosciences, Inc. (COGT) since IPO date, it would be worth $795.45 as of January 12, 2026 at a share price of $35.35. Whereas If you bought $1000 worth of Cogent Biosciences, Inc. (COGT) shares 5 years ago, it would be worth $2,933.61 as of January 12, 2026 at a share price of $35.35.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio
GlobeNewswire Inc.
4 hours ago
New Drug Application (NDA) for NonAdvSM submitted in December 2025, NDA submission for AdvSM on track for 1H 2026NDA submission for GIST on track for April 2026; bezuclastinib has the potential to be the first new therapy for second-line GIST in over
Cogent Biosciences Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 06, 2026 1:00 PM GMT
WALTHAM, Mass. and BOULDER, Colo., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins, P
Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic Mastocytosis
GlobeNewswire Inc.
Dec 30, 2025 1:00 PM GMT
WALTHAM, Mass. and BOULDER, Colo., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced it has submitted its N